Nuvectis Pharma lowers offering capacity to $5M, suspends sales under shelf prospectus

Nuvectis Pharma lowered the amount available under its sales agreement to $5 million and suspended sales under the current prospectus.

Key Highlights:

• Company reduced the amount available for sales under its Sales Agreement Prospectus to $5 million.
• The company is suspending the Sales Agreement Prospectus and will not sell shares under it until a new prospectus, supplement, or registration statement is filed.
• The Sales Agreement with Leerink Partners remains in full force and effect despite the suspension.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.